Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PLX

PLX - Protalix BioTherapeutics Inc Stock Price, Fair Value and News

$2.05-0.07 (-3.30%)
Market Closed

36/100

PLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

36/100

PLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.66

Target 3M

$1.95

Target 6M

$1.83

PLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLX Price Action

Last 7 days

-1.0%

Last 30 days

14.5%

Last 90 days

-9.3%

Trailing 12 Months

-11.3%

PLX RSI Chart

PLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLX Valuation

Market Cap

164.9M

Price/Earnings (Trailing)

30.56

Price/Sales (Trailing)

2.67

EV/EBITDA

19.15

Price/Free Cashflow

-14.1

PLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.66

Target 3M

$1.95

Target 6M

$1.83

PLX Fundamentals

PLX Revenue

Revenue (TTM)

61.8M

Rev. Growth (Yr)

-0.6%

Rev. Growth (Qtr)

14.01%

PLX Earnings

Earnings (TTM)

5.4M

Earnings Growth (Yr)

-27.22%

Earnings Growth (Qtr)

1.3K%

PLX Profitability

Operating Margin

57.54%

EBT Margin

10.49%

Return on Equity

10.2%

Return on Assets

6.56%

Free Cashflow Yield

-7.09%

PLX Investor Care

Shares Dilution (1Y)

9.22%

Diluted EPS (TTM)

0.08

PLX Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202559.8M61.9M61.8M0
202459.7M38.1M45.7M53.4M
202341.1M67.5M63.6M65.5M
202243.1M45.4M47.6M47.6M
202152.6M48.0M49.3M38.4M
202065.9M64.6M61.2M62.9M
201940.1M50.4M64.0M54.7M
201822.7M18.4M11.5M34.2M
201711.4M16.0M18.9M21.1M
20163.4M3.8M7.1M9.2M
20153.7M3.9M4.2M4.4M
201413.6M13.8M13.9M3.5M
201334.6M10.7M9.3M10.5M
20128.1M33.5M36.1M34.9M
20119.6M9.3M7.2M8.4M
20100006.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Protalix BioTherapeutics Inc

PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
 CEO
 WEBSITEprotalix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES193

Protalix BioTherapeutics Inc Frequently Asked Questions

PLX is the stock ticker symbol of Protalix BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Protalix BioTherapeutics Inc is 164.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PLX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PLX is over valued or under valued. Whether Protalix BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Protalix BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLX.

As of Wed Jan 28 2026, PLX's PE ratio (Price to Earnings) is 30.56 and Price to Sales (PS) ratio is 2.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Protalix BioTherapeutics Inc has provided -0.133 (multiply by 100 for percentage) rate of return.